SCHEMBL3583549

SCHEMBL3583549

O=C(c1cncc(C(F)(F)F)c1)c1cc(O)c(O)c([N+](=O)[O-])c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 9/20 0.69
GPR35 Q9HC97 3/20 0.52
COMT P21964 2/20 0.52
ABCC3 O15438 1/20 0.52
ABCC4 O15439 1/20 0.52
NR1I2 O75469 1/20 0.52
ABCB11 O95342 1/20 0.52
NR3C1 P04150 1/20 0.52
PGR P06401 1/20 0.52
HTR1A P08908 1/20 0.52
ADORA3 P0DMS8 1/20 0.52
RARB P10826 1/20 0.52
SLC6A2 P23975 1/20 0.52
ADORA1 P30542 1/20 0.52
ADRA1A P35348 1/20 0.52
PTGS2 P35354 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KCNH2 Q12809 1/20 0.52
KLF10 Q13118 1/20 0.52
PDE3A Q14432 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7363624 0.82 TTR (1.00) TTRGPR35COMTABCC3ABCC4
SCHEMBL3588102 0.80 TTR (0.69) TTRGPR35COMTABCC3ABCC4
SCHEMBL7368380 0.79 TTR (0.81) TTRGPR35COMTABCC3ABCC4
SCHEMBL1447200 0.79 TTR (0.67) TTRGPR35COMTABCC3ABCC4
Bromide SCHEMBL7365276 0.78 TTR (0.78) TTRGPR35COMTABCC3ABCC4
SCHEMBL27743605 0.78 CES2 (0.48) HPGDRAB9AALOX15
SCHEMBL7373087 0.75 TTR (0.59) TTRGPR35COMTABCC3ABCC4
SCHEMBL3590974 0.75 FTO (0.71) GPR35COMTABCC3ABCC4ABCB11
SCHEMBL3590969 0.75 FTO (0.71) GPR35COMTABCC3ABCC4ABCB11
SCHEMBL3586620 0.75 TTR (0.65) TTRGPR35COMTABCC3ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9446012-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-09-20 US disclosed
CN-102816157-B As the Nitrocatechol derivatives of COMT inhibitor BIAL - PORTELA & CA., S.A. (PT) 2016-05-18 CN disclosed
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2014-01-23 US disclosed
US-8536203-B2 Pharmaceutical compounds BIAL-PORTELA & CA, S.A. (PT) 2013-09-17 US disclosed
EP-2617713-A1 New Pharmaceutical Compounds BIAL - Portela & Ca., S.A. (PT) 2013-07-24 EP disclosed
US-20100168113-A1 Pharmaceutical Compounds BIAL-PORTELA & CA., S.A. (PT) 2010-07-01 US disclosed
EP-2027091-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - Portela & Ca., S.A. (PT) 2009-02-25 EP disclosed
WO-2007117165-A1 NEW PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & CA, S.A. (PT) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168113-A1 Pharmaceutical Compounds PMP22, CNR2, OPRL1 TTR 2094/4885GPR35 428/4885COMT 10/4885
US-20140024682-A1 PHARMACEUTICAL COMPOUNDS PMP22, CNR2, OPRL1 TTR 2094/4885GPR35 428/4885COMT 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.